RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Basilea Pharmaceutica AG Allschwil Stock

Basilea Pharmaceutica AG Allschwil Employees 2024

Basilea Pharmaceutica AG Allschwil Employees

225

Ticker

BSLN.SW

ISIN

CH0011432447

WKN

A0B9GA

In 2024, Basilea Pharmaceutica AG Allschwil employed 225 people, a 0% change from the 225 number of employees in the previous year.

Basilea Pharmaceutica AG Allschwil Aktienanalyse

What does Basilea Pharmaceutica AG Allschwil do?

Basilea Pharmaceutica AG is a leading biopharmaceutical company based in Basel, Switzerland. It was founded in 2000 and focuses on the research, development, and marketing of innovative drugs for the treatment of infectious diseases, cancer, and dermatological conditions. The company operates globally and currently employs over 200 employees. Basilea's main focus is on developing drugs that meet the specific needs of patients and medical professionals. It works closely with its partners and customers to ensure that its products meet the highest quality standards and meet the demands of patients. Basilea has two main divisions: infections and oncology. The company has a strong expertise in the development of antibiotics and antifungal drugs. One of its most well-known products is the antibiotic Ceftobiprol, which is used to treat bacterial infections such as pneumonia, skin, and bone infections. Another promising product is Isavuconazole, an antifungal drug used to treat fungal infections. In oncology, the business is divided into two important areas: the development and marketing of cancer drugs, and collaboration with other companies to develop tailored cancer therapies. The company works closely with other leading companies such as Pfizer, Roche, and GSK to expand its expertise in cancer research and development. Basilea's business model is based on the development of innovative drugs that meet the needs of patients and doctors. The company invests heavily in its research and development and aims to develop ethically sound and effective solutions for controlling infectious diseases and cancer. Through strategic partnerships and targeted marketing, it works to market its products worldwide and strengthen its position in the rapidly changing pharmaceutical market. Basilea sees itself as an innovative company that establishes itself in the market and plays a leading role in the industry. Its success is based on the concept of innovation, commitment, and growth. The company is committed to improving the quality of life for patients around the world by focusing on the development of new drugs that help fulfill important medical needs. Basilea Pharmaceutica AG remains committed to striving for excellence and innovation together with its partners and customers to advance the development of new treatment options. With this focus, Basilea will continue to play an important role in the industry and bring innovative drugs to the market that improve patients' lives and make the world a better place. Basilea Pharmaceutica AG Allschwil ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Basilea Pharmaceutica AG Allschwil's Employee Base

Basilea Pharmaceutica AG Allschwil's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Basilea Pharmaceutica AG Allschwil's operational capacity and future potential.

Year-to-Year Comparison

Assessing Basilea Pharmaceutica AG Allschwil's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Basilea Pharmaceutica AG Allschwil's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Basilea Pharmaceutica AG Allschwil’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Basilea Pharmaceutica AG Allschwil stock

How many employees does Basilea Pharmaceutica AG Allschwil have this year?

Basilea Pharmaceutica AG Allschwil has 225 undefined employees this year.

How many employees did Basilea Pharmaceutica AG Allschwil have compared to the previous year?

Compared to the previous year, Basilea Pharmaceutica AG Allschwil had 0% more employees.

What impact did the number of employees have on the company Basilea Pharmaceutica AG Allschwil?

The number of employees has a direct impact on the efficiency and productivity of Basilea Pharmaceutica AG Allschwil. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Basilea Pharmaceutica AG Allschwil?

The number of employees can also have an impact on investors of Basilea Pharmaceutica AG Allschwil, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Basilea Pharmaceutica AG Allschwil affect the company?

An increase in equity of Basilea Pharmaceutica AG Allschwil can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Basilea Pharmaceutica AG Allschwil's equity affect the company?

A reduction in equity of Basilea Pharmaceutica AG Allschwil can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Basilea Pharmaceutica AG Allschwil?

Some factors that can influence the equity of Basilea Pharmaceutica AG Allschwil include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Basilea Pharmaceutica AG Allschwil so important for investors?

The equity of Basilea Pharmaceutica AG Allschwil is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Basilea Pharmaceutica AG Allschwil influence the company?

The number of employees at Basilea Pharmaceutica AG Allschwil can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Basilea Pharmaceutica AG Allschwil evolved in recent years?

In recent years, the number of employees at Basilea Pharmaceutica AG Allschwil has changed by 0.

How many employees does Basilea Pharmaceutica AG Allschwil currently have?

Basilea Pharmaceutica AG Allschwil currently has 225 undefined employees.

Why is the number of employees important for investors of Basilea Pharmaceutica AG Allschwil?

The number of employees is important for investors of Basilea Pharmaceutica AG Allschwil as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Basilea Pharmaceutica AG Allschwil take to change the number of employees?

To change the number of employees, Basilea Pharmaceutica AG Allschwil can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Basilea Pharmaceutica AG Allschwil pay?

Over the past 12 months, Basilea Pharmaceutica AG Allschwil paid a dividend of 5 CHF . This corresponds to a dividend yield of about 12.48 %. For the coming 12 months, Basilea Pharmaceutica AG Allschwil is expected to pay a dividend of 0 CHF.

What is the dividend yield of Basilea Pharmaceutica AG Allschwil?

The current dividend yield of Basilea Pharmaceutica AG Allschwil is 12.48 %.

When does Basilea Pharmaceutica AG Allschwil pay dividends?

Basilea Pharmaceutica AG Allschwil pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Basilea Pharmaceutica AG Allschwil?

Basilea Pharmaceutica AG Allschwil paid dividends every year for the past 0 years.

What is the dividend of Basilea Pharmaceutica AG Allschwil?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Basilea Pharmaceutica AG Allschwil located?

Basilea Pharmaceutica AG Allschwil is assigned to the 'Health' sector.

Wann musste ich die Aktien von Basilea Pharmaceutica AG Allschwil kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Basilea Pharmaceutica AG Allschwil from 6/21/2013 amounting to 5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/11/2013.

When did Basilea Pharmaceutica AG Allschwil pay the last dividend?

The last dividend was paid out on 6/21/2013.

What was the dividend of Basilea Pharmaceutica AG Allschwil in the year 2023?

In the year 2023, Basilea Pharmaceutica AG Allschwil distributed 0 CHF as dividends.

In which currency does Basilea Pharmaceutica AG Allschwil pay out the dividend?

The dividends of Basilea Pharmaceutica AG Allschwil are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Basilea Pharmaceutica AG Allschwil

Our stock analysis for Basilea Pharmaceutica AG Allschwil Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Basilea Pharmaceutica AG Allschwil Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.